Latest news

Nanologica presents at Redeye Theme: Diabetes 23 May

22 May, 2024

Nanologica’s CEO Andreas Bhagwani will present the company at Redeye Theme: Diabetes on 23 May at 11.10. Link to follow the event

Bulletin from the AGM in Nanologica

16 May, 2024

Nanologica AB (publ) today 16 May 2024 held its Annual General Meeting in Stockholm, at which the following resolutions were adopted. Adoption of the income statement and balance sheet, disposition of result The Annual General Meeting adopted the income statement and balance sheet for the company and the group in accordance with the presented accounting documents and resolved, in accordance with the board´s proposal, that the accumulated loss of SEK -75,880,232 shall be carried forward.

Rapportkommentar Q1 2024 Nanologica AB publ

26 April, 2024

Vd Andreas Bhagwani kommenterar Nanologicas kvartalsrapport för första kvartalet 2024.

CEO Comment Q1 2024

26 April, 2024

The year has started both positively and negatively. On a positive note, we have started delivering chromatography media to customers and we achieved net sales of MSEK 5 in the first quarter. This is the company’s highest sales of chromatography products in a single quarter to date and in line with the expectations of a a sharp increase in sales of chromatography media in 2024. At the same time, the work of optimizing the production

CEO Comment from Annual Report 2023

22 March, 2024

2023 has been marked by geopolitical tensions and macroeconomic uncertainty. Like most others, Nanologica has been affected by this and we have had to prioritize our resources. On the other hand, we operate in a market segment that is virtually insensitive to economic cycles. We expect a commercial breakthrough in the near future and have a clear growth strategy for how we can capitalize on the strong market growth that exists in drugs for the

Nanologica’s Annual Report for 2023 Has Been Published

22 March, 2024

The annual report in Swedish and a translation in English is available on www.nanologica.com in a pdf format. The official original version of the annual report is prepared in Swedish in the European Single Electronic Format (ESEF). Swedish: https://nanologica.com/category/finansiella-rapporter/ English translation: https://nanologica.com/category/financial-reports/

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.

Categories

News archive